AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Genzyme Molecular Oncology Receives Patent Relating To SPHERE Technology.(Brief Article)
2002 FEB 6 - (NewsRx.com & NewsRx.net) -- Genzyme Molecular Oncology announced the issuance of U.S. Patent No. 6,338,945 ('945) relating to its high throughput screening technology known as SPHERE.
The method described in the patent entitled, "A Method for Identifying Cytotoxic T Cell (CTL) Epitopes," is broadly applicable and may be used in the selection of potential vaccine candidates, as well as the identification of novel antigens for treatment of cancer, viral infections, or autoimmune disorders. Additional patent applications on this method are pending in the U.S. and abroad.
According to Charles Nicolette, PhD, the inventor of the issued patent and leader of Genzyme Molecular Oncology's antigen discovery team, candidates identified using the patented method are generally more effective than the natural epitope in stimulating an immune response in vitro.
"In many cases, we have identified peptides that are 1000 to 100,000 times more potent than the native," stated Nicolette. "Because these peptides are screened against CTL that recognized the native epitope, we know each is therapeutically relevant."
The SPHERE (Solid PHase Epitope REcovery) technology is the key driver of Genzyme Molecular Oncology's powerful antigen discovery platform, ...
- Genzyme Molecular Oncology Stock Begins Trading Today.
- Press release article from: PR Newswire November 16, 1998 700+ words
...Corp. announced that Genzyme Molecular Oncology common stock begins trading...outstanding. In addition, Genzyme Molecular Oncology shares will be distributed...is 0.10805 share of Genzyme Molecular Oncology common stock for each...
- Genzyme Molecular Oncology Achieves Milestones Totaling $3 Million in January...
- Press release article from: PR Newswire February 7, 2000 700+ words
...7 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO) today...trials. In October 1998, Genzyme Molecular Oncology licensed its rights to...terms of this agreement, Genzyme Molecular Oncology has the potential to...
- Genzyme Molecular Oncology Announces Call For Abstracts to SAGE 2003 Conference...
- Press release article from: PR Newswire October 7, 2002 700+ words
...Understanding of Human Genome Genzyme Molecular Oncology announced today that...Maderis, president of Genzyme Molecular Oncology. "This has been a very...2003 is sponsored by Genzyme Molecular Oncology, Invitrogen, and the...
- Genzyme Molecular Oncology Expands Antiangiogenesis Focus With Appointment of...
- Press release article from: PR Newswire January 14, 2002 700+ words
...FRAMINGHAM, Mass. -- Genzyme Molecular Oncology today announced further...responsibility for directing Genzyme Molecular Oncology's research efforts...lead the project for Genzyme Molecular Oncology, and also design and...
- Genzyme Molecular Oncology Receives U.S. Patent Covering LongSAGE(TM).
- Press release article from: PR Newswire January 27, 2003 700+ words
Genzyme Molecular Oncology today announced that the United...Gail Maderis, president of Genzyme Molecular Oncology. "We are now performing...LongSAGE method is utilized by Genzyme Molecular Oncology in both its antigen discovery...
- Genzyme Molecular Oncology's SAGE (TM) Genomics Technology Utilized to Discover...
- Press release article from: PR Newswire August 17, 2000 700+ words
...17 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO) today...Hopkins University, Genzyme Molecular Oncology has rights to all intellectual...Maderis, president of Genzyme Molecular Oncology. "The results of this...
- Genzyme Molecular Oncology Receives Patent Covering Novel Peptide Corresponding...
- Press release article from: PR Newswire March 18, 2003 700+ words
Genzyme Molecular Oncology today announced that the U...director of antigen discovery for Genzyme Molecular Oncology, using the patented SPHERE...Gail Maderis, president of Genzyme Molecular Oncology. "The clinical utility of...
- Genzyme Molecular Oncology Establishes Marketing Agreement with Celera Genomics.
- Press release article from: PR Newswire September 25, 2000 700+ words
...25 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO) today...Under the agreement, Genzyme Molecular Oncology will license its SAGE...revenue sharing basis. Genzyme Molecular Oncology will provide Celera with...
Source: HighBeam Research, Genzyme Molecular Oncology Receives Patent Relating To SPHERE...